Abstract
Recent studies in hypogonadism may significantly alter the treatment population and treatment patterns in low testosterone. Whereas traditional teaching forbade testosterone replacement in men with treated or untreated prostate cancer, the literature is calling into question the science behind this dogma. Further, testosterone replacement is a cornerstone of sexual medicine yet newer studies suggest it may not add anything more to the treatment protocol than phosphodiesterase type 5 inhibitors. Testosterone replacement in the aging male has also invited controversy with some studies demonstrating greater morbidity in this population. This article will try to make sense of the conflicting literature in testosterone replacement and aid the clinician in developing a rational treatment strategy to an appropriate patient population.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
